https://www.selleckchem.com/pr....oducts/pentylenetetr
Lung metastases may worsen overall survival (OS) in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC). We investigated (post hoc) the impact of lung metastases on survival in SELECT (a phase 3 study). 392 patients with RR-DTC were randomised 21 to lenvatinib 24mg daily (n=261) or placebo (n=131). Placebo-treated patients could crossover to open-label lenvatinib following progression. Patients were grouped by size of baseline lung metastases. Safety/efficacy outcomes, collated by these lung-metastases
Like
Comment
Share
